Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Consolidated Net Income (2021 - 2025)

Historic Consolidated Net Income for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to -$12.1 million.

  • SAB Biotherapeutics' Consolidated Net Income fell 1659.63% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.6 million, marking a year-over-year increase of 657.27%. This contributed to the annual value of -$41.9 million for FY2024, which is 59.45% up from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Consolidated Net Income is -$12.1 million, which was down 1659.63% from -$9.8 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Consolidated Net Income ranged from a high of $1.4 million in Q1 2021 and a low of -$22.9 million during Q4 2023
  • For the 5-year period, SAB Biotherapeutics' Consolidated Net Income averaged around -$7.5 million, with its median value being -$7.3 million (2024).
  • Per our database at Business Quant, SAB Biotherapeutics' Consolidated Net Income tumbled by 84592.72% in 2023 and then surged by 5649.72% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Consolidated Net Income (Quarter) stood at -$11.6 million in 2021, then skyrocketed by 32.05% to -$7.8 million in 2022, then plummeted by 191.21% to -$22.9 million in 2023, then surged by 56.5% to -$9.9 million in 2024, then fell by 21.36% to -$12.1 million in 2025.
  • Its Consolidated Net Income was -$12.1 million in Q3 2025, compared to -$9.8 million in Q2 2025 and -$10.8 million in Q1 2025.